This study investigated the impact of a sequential ethanol precipitation gradient on the molecular weight distribution, chemical composition, and macromolecular architecture of Ganoderma lucidum polysaccharides. Fractions obtained via serial precipitation (30%, 60%, and 90% ethanol: GLP30, GLP60, and GLP90, respectively) and a traditional single-step precipitation (75%: GLP75) were characterized using mainly HPSEC-MALLS-RI, GC-MS, NMR spectroscopy (HSQC-DEPT), and rheological analyses. The results demonstrated that sequential precipitation effectively fractionated the polymers based on structural profiles and molecular masses. GLP30 and GLP90 primarily comprised α- and β-D-glucans (70–74% Glc), and heteropolysaccharides with mannose and arabinose, whereas GLP60 exhibited the highest structural heterogeneity, encompassing complex heteropolysaccharides and uronic acids (5.8%). The single-step GLP75 fraction yielded a heterogeneous mixture of these distinct populations. NMR spectra showed signals that corroborated the monosaccharide compositions. High-molecular-weight fractions (GLP30 and GLP75) retained rigid triple-helical conformations, displaying non-Newtonian shear-thinning behavior, a weak-gel viscoelastic profile, and remarkably high intrinsic viscosities ([η] 39.45 and 610.73 dL/g, respectively). Conversely, the low-molecular-weight fractions (GLP60 and GLP90), although retained rigid triple-helical conformations, exhibited negligible hydrodynamic volumes ([η] < 1.6 dL/g). Overall, this research provides a highly feasible strategy to successfully separate macrofungal polysaccharides according to both their molecular weight and monosaccharide distribution, minimizing some purification steps.
Ganoderma lucidum’s anticancer potential is largely attributed to its polysaccharides, yet their preclinical translation requires rigorous systematization. Following PRISMA 2020 guidelines, this systematic review evaluated the anticancer efficacy of G. lucidum polysaccharides (GLPs) in preclinical models (PROSPERO: CRD42021296200). Systematic searches spanning 2011 to 2026 were conducted in PubMed, Embase, and Scopus. Eligible peer-reviewed articles investigated GLPs in cancer cell lines or animal models. The Cochrane Risk of Bias 2 (RoB 2.0) tool was used to assess the risk of bias for animal studies. Across 14 included studies, GLPs were primarily extracted from fruiting bodies or spores via hot-water extraction and ethanol precipitation. Preclinical models predominantly involved colorectal cancer cell lines (HCT-116, HT-29, LoVo, SW480) and BALB/c, ICR, or Swiss albino mouse strains. GLPs consistently reduced tumor volume in vivo and decreased tumor cell viability in vitro. Mechanistic outcomes encompassed the induction of apoptosis, senescence, and immunomodulatory markers, frequently converging on MAPK/NF-κB signaling pathways. However, a major methodological limitation was the widespread negligence or superficiality in the chemical characterization of the tested fractions; only one study achieved complete purification of a β-D-glucan. In conclusion, while GLPs demonstrate potent tumor-suppressive and immunomodulatory properties, the pervasive structural ambiguity and lack of extract purification profoundly hinder translational reliability and the establishment of robust structure–activity relationships.